Allogeneic CAR-T cells for cancer immunotherapy

Area of Science:

• Oncology
• Immunotherapy
• Cellular Therapy

Background:

• Autologous chimeric antigen receptor (CAR)-T cell therapy is effective for hematological malignancies.
• Approved autologous CAR-T products face challenges: time-consuming, high cost, manufacturing failure, and rapid disease progression in some patients.

Purpose of the Study:

• To review universal CAR-T (U-CAR-T) cell therapy methods for malignancies.
• To summarize basic studies and clinical trials of U-CAR-T therapy.
• To identify challenges and potential solutions for U-CAR-T cell therapy.

Main Methods:

• Review of existing literature on U-CAR-T cell therapy.
• Analysis of basic research findings.
• Examination of clinical trial data for U-CAR-T applications in malignancies.

Main Results:

• U-CAR-T cell therapy presents a viable solution to the limitations of autologous CAR-T therapy.
• The review covers fundamental research and clinical investigations into U-CAR-T therapeutic approaches.
• Identified challenges and proposed solutions for U-CAR-T implementation are discussed.

Conclusions:

• Universal CAR-T cell therapy demonstrates potential to overcome autologous CAR-T limitations.
• Further research and clinical trials are essential for optimizing U-CAR-T therapy.
• Addressing current challenges will facilitate broader application of U-CAR-T for cancer treatment.